111 results
8-K/A
EX-99.1
GMDAQ
Gamida Cell Ltd
5 Apr 24
Other Events
5:16pm
and who had no available matched donor. The study evaluated the safety and efficacy of omidubicel compared to standard umbilical cord blood. BMT … %) and a safety profile similar to that reported previously.
On April 26, 2022, the Company announced that the FDA cleared its investigational new drug
8-K
EX-99.1
f94a42bl4w9mgqy39fj
14 Nov 23
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
12:00am
8-K
EX-99.1
0eez1kaqzjsc3 l1mm5
27 Sep 23
Regulation FD Disclosure
4:43pm
8-K
EX-1.1
t2o8opaf
21 Apr 23
Gamida Cell Announces Launch of Public Offering of Securities
7:19am
8-K
EX-99.1
h9h7nv
17 Apr 23
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
5:29pm
8-K
EX-99.1
lfpptyw5fc3b fd
12 Dec 22
Gamida Cell Announces Closing of $25 Million Financing with Highbridge
7:15am
8-K
EX-99.1
jfn1f3amk3528eixgr
21 Nov 22
Gamida Cell Provides Regulatory Update on Omidubicel
5:20pm
8-K
EX-99.1
xrwo5ov18d
14 Nov 22
Gamida Cell Reports Third Quarter 2022 Financial Results
7:15am
8-K
EX-1.1
sqqs8a5gerk1nlg 341h
30 Sep 22
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
4:02pm
424B5
3glyp1mxra2
29 Sep 22
Prospectus supplement for primary offering
4:08pm
424B5
nekxoc
27 Sep 22
Prospectus supplement for primary offering
5:01pm